Cancer treatment has come a long way over the years. At the forefront of these medical advances are therapies known as “biologics.” Today I am speaking with Andrew Spiegel from the Global Colon Cancer Association to talk about biosimilars in cancer treatment and how he has used his voice in patient-centered policy and other discussions to ensure safe biologic medicines are available and accessible to patients.
Special Guest: Andrew Spiegel.
At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. We have a deep and diverse pipeline of cutting-edge therapeutic approaches that aim to improve outcomes.
Amgen has been pursuing novel treatment approaches for more than 40 years.
We never stop looking toward the next frontier of innovation to bring the greatest potential benefit to patients.